Notable Labs Enters into a Collaboration Agreement with IntelliCyt
June 20, 2016
Developing predictive drug sensitivity assays using cancer patient cells is one of the promises of personalized medicine. Next generation platforms must integrate immune profiling in physiologically relevant ex-vivo microenvironments to ensure clinical translation of laboratory results.
Albuquerque, NM and San Francisco, CA – June 20, 2016. IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody discovery, and immuno-oncology research, announced a collaboration with Notable Labs to further the development of a predictive personalized medicine platform.
Notable Labs helps oncologists identify effective therapies that they can prescribe today by testing them on a patient’s own cells. This approach promises tailored treatment options fast enough for doctors to put to use. By testing a broad set of drugs and drug combinations, Notable Labs is able to functionally profile cancer cells, which leads to a better understanding of the biological mechanisms of the patient’s cancer. Providing this information to physicians can improve treatment outcomes while reducing side effects.
Notable Labs will utilize IntelliCyt’s iQue® Screener PLUS platform in a fully automated, high-throughput laboratory to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Prioritized treatment options will be highlighted in reports to clinicians using Notable Lab’s screening process with IntelliCyt’s immune-profiling technology.
The IntelliCyt iQue Screener platform, an integrated instrument, software and reagent system, offers a proprietary high-throughput sampling capability that enables the rapid assessment of cells and beads in suspension in 96-, 384-, and 1536-well plates. In addition to the fastest plate processing speed in the industry today for this type of analysis, miniaturization of the assay is possible to save reagent cost and conserve precious samples. Additionally, high content, multiplex readouts are generated on each individual cell or bead via the flow cytometry-based detection system. Data analysis and visualization using ForeCyt® software, provides unique insights into the complex biology of disease.
“IntelliCyt is expanding into the personalized medicine field by leveraging our high throughput, immune-profiling capabilities,” said Janette Phi, Chief Business Officer of IntelliCyt. “We are excited to collaborate with Notable Labs in this transformational path of enabling potentially life-saving therapies.”
“The iQue Screener PLUS offers deeper insights into which treatments target cancer cells while sparing a patient’s healthy cells”, said Matt De Silva, CEO of Notable Labs. “High-throughput flow cytometry provides us with new capabilities to observe real-time drug sensitivity for individual patients on a single cell level.”
About Notable Labs
Our mission is to change the way cancer is treated, which starts with putting patients first. Combining FDA-approved treatment options with laboratory automation and data science, we’ve built a service to help oncologists identify effective therapies that they can prescribe today. For more information, please visit www.notablelabs.com.
About IntelliCyt
IntelliCyt Corporation manufactures and sells instrumentation, software and reagents that facilitate the study of cells and their components to gain a better understanding of normal and disease processes. This information speeds the discovery and development of new drugs and provides new insight for the diagnosis of diseases. IntelliCyt’s products are used worldwide throughout the pharmaceutical and biotechnology industries and in nonprofit research labs. For more information, please visit www.intellicyt.com.